Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:CLRB
- CUSIP: N/A
- Web: www.cellectar.com
Capitalization:- Market Cap: $24.78 million
- Outstanding Shares: 13,922,000
Average Prices:- 50 Day Moving Avg: $1.63
- 200 Day Moving Avg: $1.82
- 52 Week Range: $1.12 - $3.19
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.87
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.81 per share
- Price / Book: 2.12
Profitability:- EBIDTA: ($10,780,000.00)
- Return on Equity: -97.36%
- Return on Assets: -83.40%
Debt:- Current Ratio: 5.91%
- Quick Ratio: 5.91%
Misc:- Average Volume: 231,792 shs.
- Beta: 1.05
- Short Ratio: 13.63
Frequently Asked Questions for Cellectar Biosciences (NASDAQ:CLRB)
What is Cellectar Biosciences' stock symbol?
Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."
How were Cellectar Biosciences' earnings last quarter?
Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its earnings results on Monday, August, 14th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. View Cellectar Biosciences' Earnings History.
When will Cellectar Biosciences make its next earnings announcement?
Where is Cellectar Biosciences' stock going? Where will Cellectar Biosciences' stock price be in 2017?
2 brokerages have issued twelve-month price objectives for Cellectar Biosciences' shares. Their forecasts range from $2.70 to $2.70. On average, they anticipate Cellectar Biosciences' stock price to reach $2.70 in the next year. View Analyst Ratings for Cellectar Biosciences.
Who are some of Cellectar Biosciences' key competitors?
Some companies that are related to Cellectar Biosciences include Juniper Pharmaceuticals (JNP), Amryt Pharma PLC (AMYT), Histogenics Corporation (HSGX), Pernix Therapeutics Holdings (PTX), Intellipharmaceutics International (IPCI), Apricus Biosciences (APRI), Eyegate Pharmaceuticals (EYEG), Venture Life Group PLC (VLG), Immune Pharmaceuticals (IMNP), Neuralstem (CUR), Galena Biopharma (GALE), Aegerion Pharmaceuticals (AEGR), Amryt Pharma PLC (FAST), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), CoLucid Pharmaceuticals (CLCD), Female Health Company (The) (VERU) and Forest Laboratories (FRX).
Who are Cellectar Biosciences' key executives?
Cellectar Biosciences' management team includes the folowing people:
- Stephen Anthony Hill M.D., Chairman of the Board
- James V. Caruso, President, Chief Executive Officer, Director
- Chad J. Kolean, Chief Financial Officer, Vice President - Finance, Treasurer
- Jarrod Longcor, Senior Vice President - Corporate Development and Operations
- Cameron Szakacs Ph.D., Vice President - Clinical Development
- Frederick W. Driscoll, Director
- Douglas J. Swirsky, Director
- Stefan D. Loren Ph.D., Independent Director
- John P. Neis, Independent Director
Who owns Cellectar Biosciences stock?
Cellectar Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.09%) and Virtu KCG Holdings LLC (0.48%). Company insiders that own Cellectar Biosciences stock include Awm Investment Company, Inc, James V Caruso, John Neis, Paul L Berns and Richard Hertzberg. View Institutional Ownership Trends for Cellectar Biosciences.
Who bought Cellectar Biosciences stock? Who is buying Cellectar Biosciences stock?
Cellectar Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Virtu KCG Holdings LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso, John Neis and Paul L Berns. View Insider Buying and Selling for Cellectar Biosciences.
How do I buy Cellectar Biosciences stock?
Shares of Cellectar Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectar Biosciences' stock price today?
One share of Cellectar Biosciences stock can currently be purchased for approximately $1.72.
MarketBeat Community Rating for Cellectar Biosciences (NASDAQ CLRB)MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cellectar Biosciences (NASDAQ:CLRB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $2.70 (56.98% upside) |
Analysts' Ratings History for Cellectar Biosciences (NASDAQ:CLRB)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 12/21/2016 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy | $2.70 | N/A |  |
| 12/21/2016 | Langenberg & Company | Initiated Coverage | Buy | $2.70 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Cellectar Biosciences (NASDAQ:CLRB)Earnings History by Quarter for Cellectar Biosciences (NASDAQ CLRB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2017 | | ($0.25) | | | | | N/A | |
| 8/14/2017 | Q2 2017 | ($0.24) | ($0.23) | | | View | N/A | |
| 5/11/2017 | Q1 2017 | ($0.23) | ($0.24) | | | View | N/A | |
| 3/15/2017 | Q4 2016 | ($0.23) | ($0.35) | | | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.20) | ($0.43) | | | View | N/A | |
| 8/11/2016 | Q2 2016 | ($0.40) | ($0.49) | | | View | N/A | |
| 11/12/2015 | Q315 | | ($0.25) | | | View | Listen | |
| 8/12/2015 | Q215 | | ($0.30) | | | View | Listen | |
| 5/21/2015 | Q115 | | ($0.30) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cellectar Biosciences (NASDAQ:CLRB)Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-0.92 EPS
Dividend History for Cellectar Biosciences (NASDAQ:CLRB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cellectar Biosciences (NASDAQ:CLRB)Insider Ownership Percentage: 10.17%
Institutional Ownership Percentage: 2.63%
Insider Trades by Quarter for Cellectar Biosciences (NASDAQ:CLRB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/29/2016 | John Neis | Director | Buy | 333,333 | $1.49 | $496,666.17 | |
| 10/31/2016 | Richard Hertzberg | Insider | Sell | 21,000 | $2.03 | $42,630.00 | |
| 4/20/2016 | James V Caruso | CEO | Buy | 46,948 | $2.12 | $99,529.76 | |
| 4/20/2016 | Paul L Berns | Director | Buy | 117,371 | $2.12 | $248,826.52 | |
| 12/31/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 100,000 | $0.69 | $69,000.00 | |
| 12/29/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 82,847 | $0.69 | $57,164.43 | |
| 12/28/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 367,966 | $0.73 | $268,615.18 | |
| 12/22/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 7,938 | $0.90 | $7,144.20 | |
| 12/21/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 27,621 | $0.92 | $25,411.32 | |
| 12/17/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 71,225 | $0.87 | $61,965.75 | |
| 12/15/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 44,965 | $0.82 | $36,871.30 | |
| 12/4/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 50,950 | $1.06 | $54,007.00 | |
| 11/24/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 173,802 | $1.24 | $215,514.48 | |
| 11/24/2015 | James V Caruso | CEO | Buy | 1,000 | $1.30 | $1,300.00 | |
| 11/20/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 96,806 | $1.17 | $113,263.02 | |
| 11/20/2015 | James V Caruso | CEO | Buy | 1,000 | $1.16 | $1,160.00 | |
| 11/19/2015 | James V. Caruso | CEO | Buy | 4,000 | $1.45 | $5,800.00 | |
| 10/23/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 8,866 | $2.00 | $17,732.00 | |
| 10/6/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 2,554 | $2.00 | $5,108.00 | |
| 10/5/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 7,500 | $2.04 | $15,300.00 | |
| 10/1/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 27,940 | $2.05 | $57,277.00 | |
| 9/29/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 24,801 | $2.36 | $58,530.36 | |
| 8/20/2014 | John Neis | Director | Buy | 268,711 | $3.75 | $1,007,666.25 | |
| 8/20/2014 | Simon Pedder | CEO | Buy | 13,300 | $3.75 | $49,875.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cellectar Biosciences (NASDAQ:CLRB)
Latest Headlines for Cellectar Biosciences (NASDAQ:CLRB)
| Source: |
|
| Date | Headline |
|---|
 | Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates
finance.yahoo.com - September 21 at 10:30 AM |
 | Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 20 at 11:05 PM |
| Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 6:04 PM |
| Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - September 18 at 8:46 PM |
| Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer
finance.yahoo.com - September 18 at 3:44 PM |
 | Theravance Biopharma (TBPH) versus Cellectar Biosciences (CLRB) Head-To-Head Survey
www.americanbankingnews.com - September 17 at 4:46 PM |
 | Cellectar Biosciences (CLRB) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 11:37 PM |
| Cellectar Biosciences, Inc. (CLRB) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - September 8 at 9:18 PM |
| Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 6 at 10:23 PM |
| Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference
finance.yahoo.com - September 6 at 5:16 PM |
| Cellectar Biosciences, Inc. (CLRB) Upgraded at ValuEngine
www.americanbankingnews.com - September 3 at 6:32 PM |
| Cellectar Biosciences, Inc. (CLRB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 25 at 8:28 PM |
 | Pipeline News Pushes Cellectar to Again Test 200 Day Moving Average
www.baystreet.ca - August 22 at 5:51 PM |
| Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window
globenewswire.com - August 22 at 5:51 PM |
| Cellectar Biosciences, Inc. (CLRB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 18 at 8:20 PM |
| Edited Transcript of CLRB earnings conference call or presentation 14-Aug-17 9:00pm GMT
finance.yahoo.com - August 15 at 5:59 PM |
| Cellectar Biosciences, Inc. (CLRB) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 15 at 2:22 PM |
| Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance - GlobeNewswire (press release)
globenewswire.com - August 14 at 5:42 PM |
| Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance
finance.yahoo.com - August 14 at 5:42 PM |
 | Cellectar Biosciences (CLRB) Says CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients
www.streetinsider.com - August 10 at 6:33 PM |
| Cellectar Biosciences (CLRB) Says CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced ... - StreetInsider.com
www.streetinsider.com - August 9 at 3:00 AM |
| Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients
finance.yahoo.com - August 8 at 4:59 PM |
 | Cellectar Biosciences to Host Conference Call on August 14, 2017 ... - Nasdaq
www.nasdaq.com - August 4 at 4:57 AM |
| Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance
finance.yahoo.com - August 3 at 6:51 PM |
| Cellectar Biosciences (CLRB) Enters Pact with Avicenna Oncology to Develop New PDCs for Solid Tumors
www.streetinsider.com - August 2 at 6:03 PM |
| Cellectar Biosciences, Inc. (NASDAQ:CLRB) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:20 AM |
| Cellectar Biosciences (CLRB) Enters Pact with Avicenna Oncology ... - StreetInsider.com
www.streetinsider.com - August 1 at 5:58 PM |
| Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors
finance.yahoo.com - August 1 at 5:58 PM |
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - June 15 at 11:12 PM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 15 at 6:10 PM |
| Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference - GlobeNewswire (press release)
globenewswire.com - June 7 at 2:37 PM |
| Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference
finance.yahoo.com - June 6 at 4:33 PM |
| Cellectar Biosciences to Present at the LD Micro Invitational Conference - GlobeNewswire (press release)
globenewswire.com - June 1 at 2:27 AM |
| Cellectar Biosciences to Present at the LD Micro Invitational Conference
finance.yahoo.com - May 30 at 12:02 PM |
| Cellectar Biosciences Inc (CLRB) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 23 at 5:04 PM |
| Three Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO ... - GlobeNewswire (press release)
globenewswire.com - May 18 at 4:16 PM |
| Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings
finance.yahoo.com - May 18 at 11:10 AM |
 | BRIEF-Cellectar Biosciences Q1 loss per share $0.24
www.reuters.com - May 12 at 9:56 PM |
| Edited Transcript of CLRB earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:53 PM |
| Cellectar Biosciences Inc (CLRB) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 12 at 2:02 PM |
| Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance
finance.yahoo.com - May 11 at 4:58 PM |
| Biotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences - PR Newswire (press release)
www.prnewswire.com - May 9 at 8:12 AM |
| Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and ... - Yahoo Finance
finance.yahoo.com - May 4 at 8:24 AM |
| Cellectar Biosciences (CLRB) Receives Media Sentiment Rating of 0.46
www.americanbankingnews.com - May 3 at 4:18 PM |
| Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance
finance.yahoo.com - May 2 at 4:22 PM |
| Cellectar Biosciences (CLRB) Getting Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 11:38 PM |
| Cellectar's Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical ... - Yahoo Finance
finance.yahoo.com - April 27 at 9:53 PM |
| Cellectar Biosciences (CLRB) Says CLR 131 and CLR 125 Demonstrate Increased Survival Benefit Using Multiple Doses in Preclinical Studies
www.streetinsider.com - April 27 at 9:56 AM |
| Cellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies
finance.yahoo.com - April 27 at 9:56 AM |
| Cellectar Biosciences (CLRB) Announces Patents for PDC Optical Agents in Detection of Multiple Cancers
www.streetinsider.com - April 25 at 12:11 PM |
Cellectar Biosciences (CLRB) Chart for Thursday, September, 21, 2017
